Company Filing History:
Years Active: 2014-2023
Title: Marja-Leena Laukkanen: Innovator in Allergy Immunotherapy
Introduction
Marja-Leena Laukkanen is a notable inventor based in Espoo, Finland. She has made significant contributions to the field of allergy immunotherapy, particularly focusing on hypoallergenic polypeptides. With a total of 4 patents to her name, her work has the potential to improve the quality of life for individuals suffering from allergies.
Latest Patents
One of her latest patents is titled "Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy." This invention relates to specific modified Equ c 1 polypeptides that serve as hypoallergens for desensitizing against horse allergies. The recombinant hypoallergenic Equ c 1 polypeptide comprises at least two amino acid modifications compared to the corresponding wild type Equ c 1 allergen. This innovative polypeptide activates the release of histamine from basophils to a lesser degree than the wild type allergen. Another significant patent focuses on mutant polypeptides useful as hypoallergens, specifically mutant Bet v 1 proteins, which are designed to desensitize individuals against birch pollen allergies. This invention also includes vaccine formulations comprising such polypeptides and methods of vaccination against birch pollen allergy.
Career Highlights
Throughout her career, Marja-Leena Laukkanen has worked with various organizations, including Desentum Oy and the Finnish VTT Technical Research Centre. Her work has been instrumental in advancing research in allergy treatments and has garnered attention in the scientific community.
Collaborations
Marja-Leena has collaborated with notable colleagues such as Juha Rouvinen and Kristiina Takkinen. These collaborations have contributed to her innovative research and development in the field of immunotherapy.
Conclusion
Marja-Leena Laukkanen is a pioneering inventor whose work in hypoallergenic polypeptides is making strides in allergy immunotherapy. Her contributions are vital for the advancement of treatments that can significantly benefit those with allergies.